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Abstract
Background: In patients with suspected or proven lung can-
cer, assessment of regional nodal and distant metastases is 
key before treatment planning. By introducing the endo-
bronchial ultrasound (EBUS)-guided scope into the esopha-
gus and stomach (EUS-B), liver lesions and celiac nodes can 
be visualized. To date, the utility of EUS-B in diagnosing liver 
lesions and retroperitoneal lymph nodes is unknown. Objec-
tives: To assess the feasibility, safety, and diagnostic yield of 
sampling of liver lesions and retroperitoneal nodes by EUS-B 
fine-needle aspiration (FNA) in a lung cancer staging setting. 
Method: Consecutive patients suspected of lung cancer in 2 
Danish centers between 1 January 2015 and 31 December 
2017 were included retrospectively when a lesion in the liver 
or a retroperitoneal lymph node was visualized and biopsied 
with EUS-B-FNA. Results: 23 left liver lobe lesions and 19 ret-
roperitoneal lymph nodes were sampled by EUS-B-FNA. Sen-
sitivity and diagnostic yield of sampled liver lesions were 86 
and 83%, respectively. In 19/23 patients, there was a cytopa-
thological diagnosis of malignancy. Sensitivity and diagnos-
tic yield from retroperitoneal lymph node samples were 83 
and 63%, respectively. In 10/19 patients, the diagnosis was 
malignancy. No complications were observed. Conclusion: 
EUS-B-FNA enables safe sampling of left liver lobe lesions 
and retroperitoneal lymph nodes. EUS-B should be consid-
ered as a minimally invasive technique to provide tissue 
proof of distant metastases lung cancer patients.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
In patients with non-small-cell lung cancer (NSCLC), 
accurate staging [1] is crucial for treatment allocation, 
especially for surgical lung tumor resection which is cu-
rative only in cases of localized disease. Therefore, it is 
mandatory to exclude metastases both in the mediasti-
num and below the diaphragm before the treatment deci-
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
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sion. Endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA) and endoscopic esoph-
ageal ultrasound-guided fine-needle aspiration (EUS-
FNA) have high accuracy for demonstrating lymph node 
metastases in the mediastinum [2, 3]. In the case of sus-
picious lesions below the diaphragm, abdominal ultra-
sound with percutaneous biopsy is the most often used 
technique to confirm or invalidate the suspicion. An al-
ternative, especially in difficult-to-reach lesions is EUS-
FNA, which has been demonstrated to establish tissue 
verification from suspected lesions in the liver, the left 
adrenal gland, and the abdominal lymph nodes in lung 
cancer patients [4–6]. However, very few pulmonologists 
perform conventional gastrointestinal EUS-FNA, where-
as the use of the EBUS scope in the esophagus (i.e., EUS-
B-FNA) is quickly gaining ground [2]. EUS-B-FNA is 
useful as a supplement to an endobronchial approach for 
additional sampling of mediastinal nodes [7–9]. To per-
form optimal mediastinal nodal staging, it is recom-
mended that the mediastinal nodal EBUS examination is 
complemented by either EUS-FNA or EUS-B-FNA [2]. 
A retrospective study demonstrated that for mediastinal 
staging, EUS-B was faster, patients needed less sedation 
and oxygen, and the time to discharge was shorter than 
with EBUS, but that the diagnostic yield was the same 
[10].
With regard to lesions below the diaphragm, in the 
European guidelines for combined EBUS and EUS, EUS-
FNA is recommended for tissue verification from left ad-
renal gland lesions suspected of metastases [2]. However, 
the guidelines do not mention suspicious lesions other 
than the left adrenal gland. This reflects that EUS-B-FNA 
is a relatively novel technique and that the literature con-
sequently gives us limited access to experience. With this 
background, we decided to investigate if lesions in the 
liver and retroperitoneal lymph nodes could be visualized 
and sampled by EUS-B-FNA in a lung cancer staging 
 setting. 
Methods
In 2 centers (the Unit of Respiratory Medicine, Department of 
Internal Medicine, Zealand University Hospital, Roskilde, and the 
Department of Respiratory Medicine, Næstved Hospital, Næstved, 
in Denmark), we performed a retrospective endosonography da-
tabase search with the following inclusion criteria: (a) known or 
suspected lung cancer, (b) referral between 1 January 2015 and 31 
December 2017, and (c) a lesion in the liver or a retroperitoneal 
lymph node was visualized and subsequent biopsy with EUS-B-
FNA was attempted. 
Standard of Reference
EUS-B fine-needle aspirates were considered adequate when 
cells from target tissue (liver: hepatocytes; celiac nodes: lympho-
cytes) or malignant cells were demonstrated in the sample. Sam-
ples with malignant cells were considered as true-positive.
For adequate samples with nonmalignant diagnoses at cytopa-
thological evaluation, the results were considered true-negative if 
verified at a follow-up of least 6 months (clinical course possibly 
supplemented with computed tomography [CT]). 
Diagnostic yield was defined as the number of samples in which 
EUS-B-FNA provided a specific diagnosis (malignant or nonma-
lignant) relative to the total number of EUS-B-FNA samples [11]. 
Sensitivity was defined as the number of samples in which EUS-B-
FNA provided a diagnosis of any malignancy relative to the total 
number of targeted lesions that turned out to be malignant [11]. 
Sensitivity was calculated as the “worst-case” scenario in which all 
patients with inconclusive samples or no follow-up were consid-
ered as suffering from malignant disease.
Patients in whom the suspicion of lung cancer was invalidated 
after complete workup were followed for 6 months to identify 
false-negative cases. Data were nonparametric and presented as 
median and range. Data were processed using SPSS v25 (IBM, Chi-
cago, IL, USA).
The EUS-B Procedure
Initially, a bronchoscopy and an EBUS procedure according to 
a structured protocol as described by Konge et al. [12] and Jenssen 
et al. [13] were performed with the patient lying on their back un-
der conscious sedation. Either a nasal or an oral approach was 
used. Thereafter, the EBUS endoscope was retracted from the tra-
chea to a level just above the vocal cords, and from this position 
turned slightly to the left and the back of the patient and advanced 
into the esophagus under gentle pressure while the patient was en-
couraged to swallow. Continuous ultrasound imaging was per-
formed, and the endoscope was advanced very carefully without 
pressure to a level below the diaphragm. Five milliliters of 4% Li-
docaine was applied to the pharynx and larynx prior to the EUS-B 
procedure to make it easier to introduce the endoscope in the 
esophagus. The left liver lobe was searched for by turning the 
transducer to the right side of the patient below the diaphragm. 
The hepatic veins were visualized with Doppler and the left liver 
lobe was swept for suspicious lesions. The abdominal aorta and the 
celiac trunk were identified and the search was expanded to detect 
enlarged retroperitoneal lymph nodes.
A structured protocol was followed using an EUS assessment 
tool (EUS-AT) [12–14] with 6 landmarks identified in this order: 
the liver, abdominal aorta, left adrenal gland, lymph node station 
7, and stations 4L and 4R. This validated and systematic tool is 
specifically developed for the examination of lung cancer patients. 
Furthermore, structures not included in the EUS-AT were searched 
for and visualized when CT and/or positron emission tomography 
(PET)-CT showed these to be abnormal [12–14]. 
When a target lesion was located, the needle was introduced 
through the biopsy channel of the endoscope. Power Doppler was 
used to prevent the puncture of vessels. The needle was placed in 
the lesion under real-time ultrasonic guidance and the stylet was 
then removed. Suction was applied with a syringe and the needle 
was moved back and forth inside the lesion. At least 2 samples were 
taken from each structure biopsied and the aspirates were pro-
cessed for both cytological smears and cell block analysis. 
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After the procedure, all patients were observed for 2 h before 
discharge. They were instructed to contact the departments if they 
experienced any kind of complications. Occurrence of complica-
tions would be noted in the patient record.
The pulmonologists were trained according to the apprentice-
ship principle and instructed by 2 experienced operators in how to 
search for structures both above and below the diaphragm in a 
systematic way [13]. No EUS-B simulator is available on the mar-
ket yet.
Equipment
EUS-B was performed with a flexible ultrasound bronchoscope 
(Olympus BF-UC180F or UC 180F, Olympus Medical Systems Eu-
rope, Ltd., Hamburg, Germany) in combination with a Hitachi 
ultrasound scanner with a linear scanning transducer (EUB 6500 
or Hivision Preirus, model EZU-MT28-S1) with the patient in the 
supine position during the investigation. A 19-gauge or 22-gauge 
needle was used for the aspirations (ViziShot Flex 19-gauge and 
22-gauge Olympus ViziShot and ViziShot 2; Olympus Medical 
Systems Europe, Ltd. and Cook, Limerick, Ireland). 
Results
A total of 23 samples from liver lesions and 19 from 
retroperitoneal lymph nodes were identified in 42 pa-
tients. Demographics and final diagnosis after complete 
workup are shown Table 1. No patients with a final non-
malignant diagnosis developed cancer during the 
6-month follow-up period. No complications linked to 
EUS-B procedures were observed. Of the 23 patients with 
samples from liver lesions, 1 had a final diagnosis of non-
malignant origin (sarcoidosis) and underwent a 6-month 
clinical follow-up without a diagnosis of cancer. Of the 19 
patients with samples from retroperitoneal lymph nodes, 
7 had a nonmalignant diagnosis (followed with clinical 
course: n = 4; clinical course and CT: n = 3) of: unspe-
cific changes (n = 3), infectious (n = 2), and sarcoidosis 
(n = 2). 
It was feasible to sample the liver lesion under real-
time ultrasound control. Twenty-one of 23 (91%) were 
adequate (contained hepatocytes) at cytopathological 
evaluation (Table 2). Malignancy was diagnosed in 19 
samples, i.e., there was a diagnostic yield of 83% (19/23). 
Mostly, ultrasound characteristics of liver metastases 
showed hypoechoic round lesions. Of the 2 nonmalig-
nant lesions, 1 was followed for 6 months and the nonma-
lignant result was confirmed. Follow-up of the lesions in 
the other patient with a nonmalignant finding and the 2 
patients with inadequate samples was not possible due to 
disseminated malignancy and subsequent systemic onco-
logical therapy. Thus, sensitivity of malignancy was 86% 
in the worst-case scenario (19 malignant/[19 malignant 
Table 1. Demographic data and diagnosis after complete workup
Liver Retro-
peritoneal 
lymph nodes
Demographics
Total number of patients 23 19
Male gender 12 (52) 8 (42)
Median age (range), years 72 (48–85) 73 (42–80)
Final diagnosis after complete workup
Primary pulmonary cancer:
NSCLC
Adenocarcinoma 5 (22) 2 (11)
Squamous cell carcinoma 5 (22) 1 (5)
SCLC 6 (26) 1 (5)
Large-cell neuroendocrine carcinoma 2 (9) 0
Metastasis from extrapulmonary tumor 4a (17) 2b (11)
Malignant lymphoma 0 6 (32)
Nonmalignant 1 (4) 7 (37)
Values express n (%), unless otherwise indicated. a Upper gas-
trointestinal tract: 2; colon: 1; pancreas: 1. b Malignant melanoma: 
1, pancreas: 1. NSCLC, non-small cell lung cancer; SCLC, small cell 
lung cancer.
Table 2. Cytopathological results of samples from 23 liver lesions
Size of lesion on CTa, mm 21 (9–44)
Adequate samplesb 21 (91.3)
Diagnosis from adequate samples
Malignancy 19 (90.5)
Nonmalignant 2 (9.5)
Values express n (%) or median (range). a Long-axis diameter. 
b Samples were considered adequate when they displayed liver cells 
or malignant cells.
Table 3. Cytopathological results of samples from 19 retroperito-
neal lymph nodes
Size of lesion on CTa, mm 18 (9–65)
Adequate samplesb 19 (100)
Diagnosis from adequate samples
Malignancy 10 (53)
Nonmalignant 9 (47)
Values express n (%) or median (range). a Long-axis diameter. 
b  Samples were considered adequate when they displayed lym-
phocytes or malignant cells.
EUS-B-FNA for Diagnosing Liver and 
Celiac Metastases in Lung Cancer Patients
431Respiration 2019;98:428–433
DOI: 10.1159/000501834
and 3 samples without follow-up]). All aspirated lesions 
were located in the left liver lobe. 
All 19 samples (100%) from the retroperitoneal lymph 
nodes were adequate for cytopathological evaluation (Ta-
ble 3). Ten samples received a diagnosis of malignancy 
and 2 showed nonnecrotizing granulomas consistent 
with sarcoidosis. There was a diagnostic yield of 63% 
(12/19).
For the 9 samples with a final nonmalignant diagnosis, 
6-month follow-up was performed in 7 patients (clinical 
course: n = 3, clinical course and CT: n = 4) without a di-
agnosis of cancer. Follow-up was not possible in the oth-
er 2 due to disseminated malignancy and subsequent sys-
temic oncological therapy. Thus, sensitivity of malignan-
cy was 83% in the worst-case scenario (10 malignant/[10 
malignant and 2 samples without follow-up]).
See Figure 1 and Figure 2 for case examples. 
Discussion
We present the first patient cohort showing that it is 
feasible and safe to sample live lesions and celiac nodes by 
EUS-B-FNA. These findings are important as we demon-
strate that, with the EBUS scope routinely used for medi-
astinal nodal staging for lung cancer, lesions suspected for 
a b c
Fig. 1. A patient with cough presented with a celiac retroperito-
neal lymph node 12 × 15 mm in size. Cytological examination 
showed lymphatic tissue, nonnecrotizing granulomas, and no ma-
lignant cells. Similar results were obtained with EUS-B-FNA and 
EBUS-TBNA from station 7 and EBUS-TBNA from station 11L. 
Granuloma detection was in line with a final diagnosis of sarcoid-
osis. a CT image of a celiac retroperitoneal lymph node marked 
with the orange circle. b PET-CT image showing the lymph node. 
c EUS-B image of the lymph node with the needle in. 
a b c
Fig. 2. A 77-year-old patient with no previous cancer presented 
with brain metastasis and suspicious lesions in the left adrenal 
gland, mediastinal lymph nodes, and liver. EBUS-FNA and EUS-
B-FNA were performed. Cytopathological evaluation of material 
from the left liver lobe showed malignant melanoma (PDL1-posi-
tive > 50%), but all other biopsies were benign. a CT image of 2 
suspected metastatic tumors in the liver; the tumor biopsied with 
EUS-B-FNA is marked with a circle. b EUS-B image of the tumor, 
marked with a white arrow. c EUS-B image of the tumor with the 
needle in (needle marked with white arrows).
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left live lobe metastases can be analyzed. In the hands of 
a skilled operator, mediastinal, liver, and celiac staging 
can be performed in a single endoscopy session. 
So far, the use of EUS-B below the diaphragm has al-
most exclusively been used for the analysis of the left ad-
renal gland. Only very limited literature addresses the po-
tential role of EUS-B in providing tissue proof of lesions 
below the diaphragm and thus attributing to diagnosing 
M1b and M1c disease. The left adrenal gland has been vi-
sualized and biopsied with EUS-B [15, 16]. Crombag and 
Annema [16] found that the success rate of EUS-B-FNA 
of the left adrenal gland was comparable to conventional 
EUS-FNA. Adrenal masses are found in up to 7% of pa-
tients with potentially resectable lung cancer [17]. Ap-
proximately two-thirds of these masses are benign adeno-
mas [18]. It has been shown that the left liver lobe [19] 
and retroperitoneal lymph nodes can be reached with 
EUS-B-FNA [20]. The incidence of liver metastases has 
been found to be 17.5% in SCLC patients and 3.8% in 
NSCLC patients [21]. It is essential to confirm or invali-
date the suspicion of M1 disease in these structures with 
tissue proof. The literature gives us no insight with re-
spect to the accessibility to retroperitoneal lymph nodes 
with EUS-B and the clinical importance of this. 
Traditionally, a percutaneous ultrasound-guided bi-
opsy is performed when CT and PET-CT reveal suspi-
cious lesions below the diaphragm [22]. It cannot be ex-
cluded, that some of the liver metastases biopsied in our 
study could have been reached with a percutaneous liver 
biopsy. However, in some cases, the distance from the 
transducer to the target may be shorter when performing 
EUS-B than with a percutaneous biopsy. The left liver 
lobe is accessible from the stomach and the right lobe 
from the duodenum [4, 23]. In our study, all sampled liv-
er lesions were located in the left liver lobe and the sam-
ples were obtained from the stomach.
In the newest guidelines on the use of EUS, it is recom-
mended [6] that EUS-FNA of liver lesions suspected of 
malignancy be performed (with the conventional gastro-
enterologic endoscope) when the suspected liver lesion 
cannot be reached percutaneously. However, all of our 
patients had the EUS-B biopsy performed in the same ses-
sion as EBUS, which has obvious practical advantages 
over performing endosonography and percutaneous bi-
opsy in separate sessions.
One of the most important complications of liver bi-
opsy is bleeding, with an incidence of 0.016% [24]. Infec-
tious complications are considered rare in both percuta-
neous and endoscopic ultrasound-guided biopsies [5, 
25]. No clear recommendations on administering pro-
phylactic antibiotics in connection with EUS-FNA of liv-
er lesions seem to exist, but antibiotics may be considered 
in connection with biopsy from pancreatic lesions [6]. No 
complications were seen in our study.
There are obvious logistical and practical advantages 
to performing an endosonography staging procedure 
with just 1 EBUS endoscope (EBUS + EUS-B) instead of 
2 (EBUS + conventional EUS). In the diagnosis and stag-
ing of the patient with lung cancer, performing a medias-
tinal nodal evaluation by both the EBUS and EUS-B pro-
cedures in combination is advised in order to achieve op-
timal results [2]. 
Though inclusion in this study was consecutive, a lim-
itation was a selection bias due to the retrospective design. 
Subsequent studies should include larger cohorts in a 
prospective multicenter design including exclusively 
consecutive patients.
Another limitation should be kept in mind, i.e., that a 
negative result in a biopsy always yields the risk of a false-
negative result. In this study, biopsies with negative re-
sults had a clinical follow-up of 6 months in cases where 
image control was not deemed relevant. However, poten-
tially, the proportion of false-negatives could have been 
underestimated with this approach.
A strength of this study is that it contributes to the 
knowledge of the usefulness of the EUS-B-FNA tech-
nique in the hands of the pulmonologist. It has shown 
that structures that the literature has rarely described be-
fore as attainable with this technique can be biopsied. 
Our results underline that EUS-B enables the pulmo-
nologist to biopsy lesions below the diaphragm and that 
the technique is of diagnostic value in the combined en-
dobronchial and esophageal diagnosing and staging of 
lung cancer [2]. Importantly, we show that EUS-B pro-
vides tissue proof of potential M1 lesions below the dia-
phragm from both liver lesions and retroperitoneal lymph 
nodes.
The novel insight is that EUS-B-FNA is a technically 
feasible and safe procedure that gives the pulmonologist 
access to the left liver lobe and retroperitoneal lymph 
nodes in the diagnosis and staging of patients suspected 
of lung cancer.
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